{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:47:09Z","timestamp":1773301629075,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T00:00:00Z","timestamp":1442361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Lyme disease is a leading vector-borne disease in the United States. Although the majority of Lyme patients can be cured with standard 2\u20134 week antibiotic treatment,  10%\u201320% of patients continue to suffer from prolonged post-treatment Lyme disease syndrome (PTLDS). While the cause for this is unclear, persisting organisms not killed by current Lyme antibiotics may be involved. In our previous study, we screened an FDA drug library and reported 27 top hits that showed high activity against Borrelia persisters. In this study, we present the results of an additional 113 active hits that have higher activity against the stationary phase B. burgdorferi than the currently used Lyme antibiotics. Many antimicrobial agents (antibiotics, antivirals, antifungals, anthelmintics or antiparasitics) used for treating other infections were found to have better activity than the current Lyme antibiotics. These include antibacterials such as rifamycins (3-formal-rifamycin, rifaximin, rifamycin SV), thiostrepton, quinolone drugs (sarafloxacin, clinafloxacin, tosufloxacin), and cell wall inhibitors carbenicillin, tazobactam, aztreonam; antifungal agents such as fluconazole, mepartricin, bifonazole, climbazole, oxiconazole, nystatin; antiviral agents zanamivir, nevirapine, tilorone; antimalarial agents artemisinin, methylene blue, and quidaldine blue; antihelmintic and antiparasitic agents toltrazuril, tartar emetic, potassium antimonyl tartrate trihydrate, oxantel, closantel, hycanthone, pyrimethamine, and tetramisole. Interestingly, drugs used for treating other non-infectious conditions including verteporfin, oltipraz, pyroglutamic acid, pidolic acid, and dextrorphan tartrate, that act on the glutathione\/\u03b3-glutamyl pathway involved in protection against free radical damage, and also the antidepressant drug indatraline, were found to have high activity against stationary phase B. burgdorferi. Among the active hits, agents that affect cell membranes, energy production, and reactive oxygen species production are more active against the B. burgdorferi persisters than the commonly used antibiotics that inhibit macromolecule biosynthesis. Future studies are needed to evaluate and optimize the promising active hits in drug combination studies in vitro and also in vivo in animal models. These studies may have implications for developing more effective treatments of Lyme disease.<\/jats:p>","DOI":"10.3390\/antibiotics4030397","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T10:33:36Z","timestamp":1442399616000},"page":"397-410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library"],"prefix":"10.3390","volume":"4","author":[{"given":"Jie","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,  Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Weitner","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,  Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanliang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,  Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,  Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,  Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-307X","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health,  Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,9,16]]},"reference":[{"key":"ref_1","unstructured":"Centers for Disease Control and Prevention Lyme Disease, Available online: http:\/\/www.cdc.gov\/lyme\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/ciu397","article-title":"Lyme disease testing by large commercial laboratories in the United States","volume":"59","author":"Hinckley","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrmicro2714","article-title":"Of ticks, mice and men: Understanding the dual-host lifestyle of lyme disease spirochaetes","volume":"10","author":"Radolf","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the infectious diseases society of america","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention Post Treatment Lyme Disease, Available online: http:\/\/www.cdc.gov\/lyme\/postLDS."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e0116767","DOI":"10.1371\/journal.pone.0116767","article-title":"Health care costs, utilization and patterns of care following lyme disease","volume":"10","author":"Adrion","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11136-012-0126-6","article-title":"Post-treatment lyme disease syndrome symptomatology and the impact on life functioning: Is there something there?","volume":"22","author":"Aucott","year":"2013","journal-title":"Qual. Life Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF02770837","article-title":"A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic lyme disease, even from those previously aggressively treated","volume":"26","author":"Phillips","year":"1998","journal-title":"Infection"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.00788-09","article-title":"Ineffectiveness of tigecycline against persistent Borrelia burgdorferi","volume":"54","author":"Barthold","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e29914","DOI":"10.1371\/journal.pone.0029914","article-title":"Persistence of Borrelia burgdorferi in Rhesus macaques following antibiotic treatment of disseminated infection","volume":"7","author":"Embers","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e86907","DOI":"10.1371\/journal.pone.0086907","article-title":"Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice","volume":"9","author":"Hodzic","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/jcm.35.1.111-116.1997","article-title":"Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment","volume":"35","author":"Straubinger","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/cid\/cit939","article-title":"Xenodiagnosis to detect Borrelia burgdorferi infection: A first-in-human study","volume":"58","author":"Marques","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.01050-07","article-title":"Persistence of Borrelia burgdorferi following antibiotic treatment in mice","volume":"52","author":"Hodzic","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01716077","article-title":"Borrelia burgdorferi DNA in the urine of treated patients with chronic lyme disease symptoms. A PCR study of 97 cases","volume":"24","author":"Bayer","year":"1996","journal-title":"Infection"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.micro.112408.134306","article-title":"Persister cells","volume":"64","author":"Lewis","year":"2010","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, Y. (2014). Persisters, persistent infections and the yin-yang model. Emerg. Microbes Infect., 3.","DOI":"10.1038\/emi.2014.3"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Feng, J., Wang, T., Shi, W., Zhang, S., Sullivan, D., Auwaerter, P.G., and Zhang, Y. (2014). Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg. Microbes Infect., 3.","DOI":"10.1038\/emi.2014.53"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e0117207","DOI":"10.1371\/journal.pone.0117207","article-title":"Drug combinations against Borrelia burgdorferi persisters in vitro: Eradication achieved by using daptomycin, cefoperazone and doxycycline","volume":"10","author":"Feng","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_20","first-page":"97","article-title":"Evaluation of in vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi","volume":"4","author":"Sapi","year":"2011","journal-title":"Infect. Drug Resist."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Feng, J., Shi, W., Zhang, S., and Zhang, Y. (2015). Identification of new compounds with high activity against Borrelia burgdorferi persisters from the nci compound collection. Emerg. Microbes Infect., 4.","DOI":"10.1038\/emi.2015.31"},{"key":"ref_22","unstructured":"US National Library of Medicine Zanamivir Oral Inhalation, Available online: http:\/\/www.nlm.nih.gov\/medlineplus\/druginfo\/meds\/a699021.html."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1172\/JCI27920","article-title":"Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production","volume":"116","author":"Soon","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10715760903380458","article-title":"Verteporfin-photoinduced apoptosis in HepG2 cells mediated by reactive oxygen and nitrogen species intermediates","volume":"44","author":"Chiou","year":"2010","journal-title":"Free Radic. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1073\/pnas.70.5.1447","article-title":"The gamma-glutamyl cycle in the choroid plexus: Its possible function in amino acid transport","volume":"70","author":"Tate","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-2797(97)00146-4","article-title":"Glutathione: An overview of biosynthesis and modulation","volume":"111\u2013112","author":"Anderson","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"ref_27","unstructured":"U.S. National Library of Medicine Verteporfin Injection, Available online: http:\/\/www.nlm.nih.gov\/medlineplus\/druginfo\/meds\/a607060.html."},{"key":"ref_28","unstructured":"Novartis Company Visudyne: Verteporfin. Available online: http:\/\/www.novartis.com.au\/PI_PDF\/vid.pdf."},{"key":"ref_29","first-page":"1230","article-title":"Role of reactive oxygen species (ros) in patients with erythema migrans, an early manifestation of lyme borreliosis","volume":"7","author":"Pancewicz","year":"2001","journal-title":"Med. Sci. Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-s-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1076","article-title":"Translational strategies for cancer prevention in liver","volume":"3","author":"Kensler","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1128\/AAC.00680-13","article-title":"High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors","volume":"57","author":"Siles","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hayek, S.R., Lee, S.A., and Parra, K.J. (2014). Advances in targeting the vacuolar proton-translocating ATPase (V-ATPase) for anti-fungal therapy. Front. Pharmacol., 5.","DOI":"10.3389\/fphar.2014.00004"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10236","DOI":"10.1074\/jbc.M111.321133","article-title":"Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domain of v0 subunit a (vph1p)","volume":"287","author":"Chan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/37551","article-title":"Genomic sequence of a lyme disease spirochaete, Borrelia burgdorferi","volume":"390","author":"Fraser","year":"1997","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical opthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02853166","article-title":"Effects of common ophthalmic preservatives on ocular health","volume":"18","author":"Noecker","year":"2001","journal-title":"Adv. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.foodcont.2008.08.002","article-title":"Comparison among the effectiveness of ozone, nisin and benzalkonium chloride for the elimination of planktonic cells and biofilms of Staphylococcus aureus cect4459 on polypropylene","volume":"20","author":"Cabo","year":"2009","journal-title":"Food Control"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/antibiotics4020179","article-title":"Identification of anti-persister activity against uropathogenic Escherichia coli from a clinical drug library","volume":"4","author":"Niu","year":"2015","journal-title":"Antibiotics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2474","article-title":"Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections","volume":"9","author":"Hurdle","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Feng, J., Shi, W., Zhang, S., and Zhang, Y. (2015). Persister mechanisms in Borrelia burgdorferi: Implications for improved intervention. Emerg. Microbes Infect., 4.","DOI":"10.1038\/emi.2015.51"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1128\/AAC.00864-15","article-title":"Borrelia burgdorferi, the causative agent of lyme disease, forms drug-tolerant persister cells","volume":"59","author":"Sharma","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e111809","DOI":"10.1371\/journal.pone.0111809","article-title":"An optimized SYBR Green I\/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi","volume":"9","author":"Feng","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: Chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"key":"ref_46","unstructured":"PUBCHEM PROMISCUITY. Available online: http:\/\/chemutils.florida.scripps.edu:8080\/pcpromiscuity\/pcpromiscuity.html."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/4\/3\/397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:48:39Z","timestamp":1760215719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/4\/3\/397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,16]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["antibiotics4030397"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics4030397","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,16]]}}}